Dan Spira was a former Vice President at Valeant Pharmaceuticals from 2011 to 2015 including Managing Director of iNova Pharmaceuticals and Bausch + Lomb. He was MD of iNova when it was originally sold to Valeant and has now returned as its CEO. The prior 15 years were spent at Johnson & Johnson in various local, regional and global roles as VP, GM and Chief Marketing Officer.

Our regional leads are responsible for all Sales, Marketing, Local supply Chain and Regulatory functions within their countries


Managing Director Australia & New Zealand

Mark joined iNova in 2015 and will continue in his role leading iNova’s largest market. Prior to iNova Mark had Managing Director roles at Allergan and Serono and also senior commercial experience at a number of other pharma and medical device companies.


Managing Director Africa

Kym has been leading the iNova South Africa business since 2013 and prior to that was in General Management positions at Adcock Ingram.


President of Asia (VACANT ROLE)

We look forward to announcing the new President of Asia shortly. This person will join iNova on 19 January 2018, bringing with him a wealth of regional experience.

At a corporate level we will have the following functions (“centres of excellence”) that will support our country teams and also work on future business growth initiatives.


Chief Financial Officer

Joe joined iNova in 2013 as CFO for Australia and New Zealand and will now broaden his responsibilities across all iNova markets. Prior to iNova, Joe held CFO positions in Novartis both in Australian and also in Asia (Singapore and Thailand).


Chief Operating Officer

Between 2011-2015 Geoff was Supply Chain Director for the iNova group and also Valeant’s Asia Pacific and Africa head of Supply Chain. Before Valeant Geoff held senior supply chain and operations roles in Australia and Asia.


General Counsel / Head of Legal & Compliance

Kate joins us from Mundipharma where she has most recently been head of legal & compliance for their Australian business. Prior to Mundipharma Kate was in senior legal roles at Novartis, Fairfax and was a lawyer at Mallesons


Chief Business Development / M&A Officer

Andrew was most recently head of Business Development for Merck’s oncology business and was previously head of Business Development / M&A at Valeant


Strategy & Transformation Director

Blane has held senior strategy and commercial roles across FMCG and Industrial Services companies including other PEP / Carlyle owned companies. He also has a consulting background through Bain & Company.